β-Arrestin2 influences the response to methadone in opioid-dependent patients.
about
An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-AmericansA polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependenceABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics.Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics.Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction.Association study of the β-arrestin 2 gene (ARRB2) with opioid and cocaine dependence in a European-American population.Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females.Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis.Pharmacogenomics of methadone maintenance treatment.Pharmacoepigenomics of opiates and methadone maintenance treatment: current data and perspectives.Arresting the Development of Addiction: The Role of β-Arrestin 2 in Drug Abuse.Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate.Pharmacogenetics of opiates in clinical practice: the visible tip of the iceberg.Impact of SNP-SNP interaction among ABCB1, ARRB2, DRD1 and OPRD1 on methadone dosage requirement in Han Chinese patients.Relationship between ABCB1 polymorphisms and serum methadone concentration in patients undergoing methadone maintenance therapy (MMT).Variability of response to methadone: genome-wide DNA methylation analysis in two independent cohorts.
P2860
Q30543145-812BB1EA-4519-455A-A322-3C6FA543E7B6Q30855550-4D44F0B1-B202-4046-8905-2E47A651F433Q36441533-AE9D27D4-907B-41DA-B4D0-3536583EB608Q36499673-76098919-5382-4FD0-8578-93A10B7E0F21Q37401604-FA42E9DD-DC12-4E99-8F89-8B40C5E27502Q37576232-E0B3DFDA-3C82-40AB-AE68-BF0BC4D3C575Q37705283-996FD8EF-FB08-4107-8D0B-99FCADCCA42EQ38184547-96EB1BA6-21DC-4A16-895F-74376D666B34Q38222510-6D15E683-8587-4335-825F-6AF9B8CF5873Q38608450-FF0C7DB7-F83A-4A26-B3BE-0D1A79D019B7Q39182855-A4970158-B7CB-45BD-A6BD-FB8D1A29D8B9Q48244859-724B4B59-4C0E-43C5-BED5-6797A5900F10Q48490118-24F39A82-AD97-4FF6-81F0-921DFAEDAF03Q49664350-13B99002-C3BC-490D-BAB7-22BA98549020Q51710092-E59644E7-BEBD-4D7B-8B1A-D2CE8AA0D151Q52308504-F894E96A-771B-4FBC-9753-AEE7F61A32F9
P2860
β-Arrestin2 influences the response to methadone in opioid-dependent patients.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
β-Arrestin2 influences the response to methadone in opioid-dependent patients.
@en
β-Arrestin2 influences the response to methadone in opioid-dependent patients.
@nl
type
label
β-Arrestin2 influences the response to methadone in opioid-dependent patients.
@en
β-Arrestin2 influences the response to methadone in opioid-dependent patients.
@nl
prefLabel
β-Arrestin2 influences the response to methadone in opioid-dependent patients.
@en
β-Arrestin2 influences the response to methadone in opioid-dependent patients.
@nl
P2093
P2860
P356
P1476
β-Arrestin2 influences the response to methadone in opioid-dependent patients
@en
P2093
M Croquette-Krokar
P2860
P2888
P304
P356
10.1038/TPJ.2010.37
P50
P577
2010-06-01T00:00:00Z